Innovations in Transcatheter Stents and Transcatheter Aortic Valves
Scripp Business Insights, November 2011, Pages: 70
This report covers innovations across the percutaneous transluminal coronary angioplasty and transcatheter aortic valve spaces. Innovations in both devices and techniques are reviewed. Devices covered include drug eluting stents, drug coated balloons, embolic protection devices and trascatheter valves. The report also examines the regulatory status of products under investigation.
Features and benefits:
- Assess the markets for percutaneous transluminal coronary angioplasty devices and transcatheter valves.
- Forecast epidemiology of key cardiology indications which impact the PTCA and transcatheter aortic valve markets.
- Evaluate innovations in percutaneous transluminal coronary angioplasty devices.
- Analyze how percutaneous transluminal coronary angioplasty techniques are changing.
- Gain an understanding of the leading transcatheter aortic valves which are under investigation for approval.
Highlights:
- The global market for percutaneous transluminal angioplasty is valued at $9.1bn in 2010, and is set to grow at a CAGR of 13.8% to reach $19.1bn in 2016. The market is being driven by the rise in procedural volumes with an increase in the average age of the population in the US and Japan, and the increase in the penetration of PCI in Asia.
- Future directions in the DES space focus on inventing DES that are safer (lower risk of thrombosis), more maneuverable in order to treat dispersed lesions, and have novel therapeutic properties, such as self-expandable DES, bifurcation stents and DES with more than one drug offering.
- New imaging techniques are the main area of innovation in transcatheter aortic valves. Edwards Lifesciences Sapien valve became the first product to be approved in the US.
Your key questions answered:
- How are PTCA techniques changing?
- Which companies are developing transcatheter aortic valves and what stages of development are they at?
- What factors are driving the PTCA device market?
- Where is the greatest potential for drug coated balloons?
- How are adjunct therapies for PTCA being used?
EXECUTIVE SUMMARY
Overview of percutaneous coronary intervention
Innovations in PCI products
Innovations in PCI techniques
Innovations in transcatheter aortic valves
Overview of percutaneous coronary intervention
Summary
Introduction
Epidemiology of cardiovascular diseases
Introduction to PCI
PCI procedure
Market size and forecasts for PCI
Historical market size and forecasts
Innovations in PCI products
Summary
Introduction
Innovations
Balloon catheters
Drug-eluting stents
Drug coated balloons
Embolic protection devices
Vascular access closure devices
Innovations in PCI techniques
Summary
Introduction
Innovations
Intravascular ultrasonography
Coronary physiologic assessment
Hybrid coronary intervention
Adjunct PCI therapies
Anti-coagulants used in PCI
Innovations in transcatheter aortic valves
Summary
Introduction
Etiology of valve disease
Introduction to TAVI
Implantation technique
Market opportunities in TAVs
Innovations in TAV
Sapien valve
CoreValve prosthesis
Other investigational devices
Leading trancatheter aortic valve manufacturers
Appendix
Scope
Methodology
Glossary/Abbreviations
Bibliography/References
TABLES
Table: Epidemiology of major cardiovascular diseases, 2010
Table: Forecast epidemiology of dyslipidemia across the 7MM, 2010–16
Table: Forecast epidemiology of stroke across the 7MM, 2010–16
Table: Leading players in the global drug-coated balloon market
Table: Developmental stages of selected drug-coated balloon devices
Table: Standard derived IVUS measurements
Table: Leading TAV manufacturers
Table: Leading TAV manufacturers (contd.)
FIGURES
Figure: Rotational atherectomy catheter
Figure: Global PCI devices market ($bn), 2010–16
Figure: Potential market size for various applications of DCBs in the US, 2012
Figure: Proximal occlusion device
Figure: Fibernet device mounted on a guidewire
Figure: Fibernet filter in the arterial vessel wall
Figure: Vascular access closure device
Figure: Normal coronary artery structure on IVUS
Figure: Fractional flow reserve measurement using Intracoronary physiologic assessment
Figure: Ishimaru classification of the thoracic aortic landing zones
Figure: Normal aortic valve vs. bicuspid aortic valve
Figure: Mechanical valve
Figure: Tissue valve
Figure: Transcatheter heart valve
Figure: Transfemoral aortic valve implantation
Figure: Transapical aortic valve implantation
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
